Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mFOLFOX + radiation therapy
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Intravenous, External Beam Radiation
01
Overview
mFOLFOX + radiation therapy is a combination treatment regimen used primarily for certain gastrointestinal cancers such as rectal and esophageal cancer. The "mFOLFOX" component refers to a modified version of the FOLFOX chemotherapy protocol, which includes three drugs: - oxaliplatin (a platinum-based DNA crosslinker), - folinic acid (leucovorin/calcium folinate), which enhances the effect of fluorouracil, - fluorouracil (5-FU), an antimetabolite that inhibits thymidylate synthase and disrupts DNA synthesis. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. When combined with mFOLFOX chemotherapy, this approach is called chemoradiotherapy or chemoradiation. This combination is used in both neoadjuvant (preoperative) and definitive settings for locally advanced rectal cancer and other gastrointestinal malignancies[1][2][4]. The mechanism involves direct cytotoxicity from chemotherapy agents plus local tumor control from radiotherapy.
- Other names
- folinic acid/fluorouracil/oxaliplatin + radiation therapy
02
Targets
TS (Thymidylate synthase)Pt-DNA adduct (DNA-oxaliplatin adduct)
Beyond the preview
Go deeper on mFOLFOX + radiation therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mFOLFOX + radiation therapy.